MedinCell S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MEB.F | URGN | 0RC6.IL | ATAI | 1875.HK | SPL.AX | |
|---|---|---|---|---|---|---|
| Market cap | 1.01B | 1.41B | 1.22B | — | 2.56B | 222.14M |
| P/E (TTM) | — | — | 60.6 | — | — | — |
| Forward P/E | — | 10.4 | — | — | 42.9 | 102.2 |
| Price/book | 332.2 | -13.2 | 5.8 | — | 3.8 | 13.9 |
| Dividend yield | — | — | 2.09% | — | — | — |
| 1-year change | −11.81% | +22.09% | −8.11% | — | +69.54% | +37.88% |
| Today | +1.15% | −16.45% | +1.58% | 0.00% | +5.54% | +1.10% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All MEB.F news ›Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Shopify Sustains Rapid Growth with Revenue Up 32% and Free Cash Flow Margin of 22% Hydrofarm Eliminates $109 Million in Debt, Becoming…
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enable controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or…
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
BioSpace Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan Since July 2026, Medincell has secured €
MedinCell Halts Euronext Trading Ahead of Market-Sensitive Announcement
An update from MedinCell SA ( (FR:MEDCL) ) is now available. MedinCell SA requested and obtained a temporary suspension of trading in its shares on Euronext Paris from 9:00 a.m. CEST, ahead of a scheduled company announcement, with trading…
FDA Approves Medincell’s Weltruza for Adults with Schizophrenia
Teva Pharmaceuticals plans to make Weltruza available in the U.S. in the coming weeks. Editor’s Take: With no loading doses, oral supplementation, or post-injection monitoring, this FDA approval addresses a gap in schizophrenia care.…
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts. A replay of the webcast will be available on Medincell's website following th
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biospace.com2
- businesswire.com1
- contractpharma.com1
- stocktitan.net1
- theglobeandmail.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.